Oligonucleotide CMC Process Development

Oligonucleotide CMC process development focuses on establishing a robust and reproducible manufacturing process for oligonucleotide drug substances and supporting the transition from early development to clinical and commercial manufacturing. It integrates synthesis, purification, process characterization, analytical evaluation, impurity control, scale-up, and manufacturing considerations to ensure that the developing process can consistently produce oligonucleotide drug substances with appropriate quality attributes. Protheragen provides Oligonucleotide CMC Process Development services covering process strategy development, synthesis and purification process integration, critical process parameter evaluation, impurity control, process characterization, scale-up assessment, analytical integration, and manufacturing readiness.

Overview of Oligonucleotide CMC Process Development

CMC, or Chemistry, Manufacturing, and Controls, provides the framework for defining how an oligonucleotide drug substance is manufactured and controlled throughout development. For chemically synthesized oligonucleotides, CMC development extends beyond the optimization of individual chemical reactions and requires coordinated evaluation of synthesis, cleavage and deprotection, purification, isolation, analytical testing, process controls, and scale-up.

Oligonucleotide molecules can present distinctive manufacturing challenges because their quality profiles are influenced by sequence length, nucleotide composition, backbone chemistry, sugar modifications, terminal modifications, conjugation structures, and synthesis conditions. The stepwise nature of oligonucleotide synthesis can also result in product-related impurities such as truncated sequences, modified species, and other closely related impurities. A comprehensive CMC development strategy therefore needs to consider the relationship between process parameters, impurity formation, purification performance, and final product quality.

Fig.1 Overview of the current oligonucleotide manufacturing process. (Andrews BI, et al., 2021)

Our Services

Protheragen provides integrated oligonucleotide CMC process development services covering process strategy, synthesis and purification, impurity control, process characterization, and scale-up. Development activities are tailored to the molecular characteristics and manufacturing requirements of each oligonucleotide program.

Key Components of Oligonucleotide CMC Development

Key Process Development Considerations

A robust oligonucleotide CMC process requires consideration of multiple interconnected factors rather than optimization of individual process steps in isolation.

Considering these factors together helps establish a process that is not only chemically effective but also suitable for controlled manufacturing and subsequent CMC development.

Applications of Oligonucleotide CMC Process Development

Protheragen's oligonucleotide CMC process development capabilities can support:

• Antisense oligonucleotide development
• siRNA drug development
• PMO development
• CpG oligonucleotide development
• Chemically modified oligonucleotides
• Conjugated oligonucleotide programs
• Preclinical oligonucleotide candidates
• IND-enabling CMC development
• Clinical-stage drug substance development
• Manufacturing process scale-up

Why Choose Protheragen

• Integrated Oligonucleotide Development

Protheragen integrates synthesis, purification, analytical evaluation, process development, and manufacturing considerations within the oligonucleotide CDMO workflow.

• Modality-specific Process Strategies

CMC development can be tailored to ASOs, siRNAs, PMOs, CpG oligonucleotides, and other chemically modified oligonucleotide candidates according to their specific molecular and manufacturing characteristics.

• Scale-up-oriented Development

Process development considers scalability from an early stage, supporting the transition from laboratory development to larger-scale and GMP manufacturing. TJR Bio, the referenced supplier platform, reports experience spanning milligram-to-kilogram oligonucleotide production and dedicated CMC process development and pilot production facilities.

• Integrated Analytical Support

Analytical evaluation is incorporated into process development to support impurity assessment, process optimization, CQA evaluation, and manufacturing control.

• Manufacturing-focused Process Development

The objective of CMC development is to establish a practical, reproducible, and scalable manufacturing process that can support later-stage development rather than optimizing individual laboratory steps independently.

A robust CMC process provides the foundation for consistent oligonucleotide drug substance manufacturing. By integrating synthesis, purification, impurity control, analytical evaluation, process characterization, and scale-up considerations, Protheragen supports the development of manufacturing processes that can progress from early-stage development toward clinical and commercial production. Our Oligonucleotide CMC Process Development services can be tailored to the molecular characteristics, development stage, and manufacturing objectives of each program, helping establish a structured pathway from process development to drug substance manufacturing. Contact us to discuss your oligonucleotide CMC development requirements, including process optimization, purification development, process characterization, scale-up, and manufacturing readiness.